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ABSTRACT
Backgound The number of patients with chronic
gastrointestinal (GI) symptoms after cancer therapies
which have a moderate or severe impact on quality of life
is similar to the number diagnosed with inﬂammatory
bowel disease annually. However, in contrast to patients
with inﬂammatory bowel disease, most of these patients
are not referred for gastroenterological assessment.
Clinicians who do see these patients are often unaware
of the beneﬁts of targeted investigation (which differ
from those required to exclude recurrent cancer), the
range of available treatments and how the pathological
processes underlying side effects of cancer treatment
differ from those in benign GI disorders. This paper aims
to help clinicians become aware of the problem and
suggests ways in which the panoply of syndromes can
be managed.
Methods A multidisciplinary literature review was
performed to develop guidance to facilitate clinical
management of GI side effects of cancer treatments.
Results Different pathological processes within the GI
tract may produce identical symptoms. Optimal
management requires appropriate investigations and
coordinated multidisciplinary working. Lactose
intolerance, small bowel bacterial overgrowth and bile
acid malabsorption frequently develop during or after
chemotherapy. Toxin-negative Clostridium difﬁcile and
cytomegalovirus infection may be fulminant in
immunosuppressed patients and require rapid diagnosis
and treatment. Hepatic side effects include reactivation
of viral hepatitis, sinusoidal obstruction syndrome,
steatosis and steatohepatitis. Anticancer biological
agents have multiple interactions with conventional
drugs. Colonoscopy is contraindicated in neutropenic
enterocolitis but endoscopy may be life-saving in other
patients with GI bleeding. After cancer treatment, simple
questions can identify patients who need referral for
specialist management of GI symptoms. Other
troublesome pelvic problems (eg, urinary, sexual,
nutritional) are frequent and may also require specialist
input. The largest group of patients affected by chronic
GI symptoms are those who have been treated with
pelvic radiotherapy. Their complex symptoms, often
caused by more than one diagnosis, need systematic
investigation by gastroenterologists when empirical
treatments fail. All endoscopic and surgical interventions
after radiotherapy are potentially hazardous as
radiotherapy may induce signiﬁcant local ischaemia. The
best current evidence for effective treatment of
radiation-induced GI bleeding is with sucralfate enemas
and hyperbaric oxygen therapy.
Conclusions All cancer units must develop simple
methods to identify the many patients who need help
and establish routine referral pathways to specialist
gastroenterologists where patients can receive safe and
effective treatment. Early contact with oncologists and/
or specialist surgeons with input from the patient’s
family and friends often helps the gastroenterologist to
reﬁne management strategies. Increased training in the
late effects of cancer treatment is required.
BACKGROUND
Improvements in the outcome for patients with
cancer over the last 30 years have reﬂected earlier
diagnosis and advances in multimodality treat-
ments. There has been a threefold increase in
survival and, although some patients are not cured,
their cancer is controlled, often for very long
periods. Others may be cured but suffer side effects
of their otherwise successful therapies. The
National Survivorship Initiative
1 has identiﬁed four
key needs of cancer survivors:
1. a personalised ‘survivorship’ care plan formu-
lated for each patient on completion of
treatment;
2. support to self-manage their condition if
appropriate;
3. provision of information on long-term effects of
living with and beyond cancer;
4. access to specialist medical care for complica-
tions that occur after cancer.
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Key facts
< There has been a threefold increase in the
numbers of survivors of cancer in the last
30 years
< Chronic gastrointestinal side effects are
a common cause of morbidity and reduced
quality of life
< Side effects of treatment are frequently missed
or overlooked because the current priority of
cancer follow-up is to perform surveillance for
recurrent cancer
< Individual GPs are unlikely to have many
patients with complex problems after cancer
therapy and so will require guidance if these
patients are to be optimally managed
< Symptoms can often be alleviated or cured.
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GuidelinesPotentially serious complications are an inevitable conse-
quence of radical therapies. Profound fatigue is not unusual;
emotional and psychological difﬁculties are common.
However, of the two million people currently living with or
cured of cancer in the UK, 25% report chronic physical
problems following treatment which impair their quality of
life.
1e3
Gastrointestinal (GI) symptoms are the most common of all
the chronic physical side effects of cancer treatment and have
the greatest impact on quality of life.
4 Fewer than 20% of
affected patients are referred to a GI specialist
5 because clear
management algorithms and routine referral pathways are
not in place and the treatable aspects of the symptom complexes
go unrecognised. When patients are referred, they usually meet
a clinician who has had no formal training in the management
of late effects of cancer treatment. Clinicians are further
hampered by limited research into the range of problems or their
optimal treatment,
67and few gastroenterologists or GI surgeons
feel conﬁdent in managing such patients.
5 As a result, these
patients needdbut fail to getdappropriate assessment.
8 Inef-
fective and potentially harmful treatments are prescribed,
1679
and some patients may be forced unnecessarily to withdraw
from work and society.
10 Sometimes continuing symptoms
compromise or prevent ongoing anticancer treatment. In
a few patients, chronic symptoms mask the early diagnosis of
recurrent or second cancers.
This guidance has been designed to facilitate clinical prac-
tice. It focuses on the physical causes of symptoms rather than
the psychological, because gastroenterologists are already very
familiar with identifying psychological factors in GI disease.
While these patients are exposed to a unique set of psycho-
logical stresses which in turn may produce GI symptoms,
there are robust data that organic causes for symptoms are
frequently missed. This guidance will therefore emphasise
those areas where symptoms starting after cancer treatments
can be considered in the same way as other GI diseases and
when clinicians need to be wary. It deﬁnes principles of
management where possible and outlines research priorities
f o rt h ef u t u r e .T h e r ei sv e r yl i t t l el e v e lA( r a n d o m i s e d
c o n t r o l l e dt r i a l )o rl e v e lB( o u tcomes research) evidence to
deﬁne optimal management of these patients or to produce
deﬁnitive guidelines. In the absence of anything better, the
recommendations presented in this guidance to inform
practical approaches to treatment are largely based on level C
(case series) and level D (expert opinion, physiological and
laboratory studies) data.
PATHOPHYSIOLOGY OF SIDE EFFECTS OF CANCER THERAPIES
Chemotherapy
Cytotoxic chemotherapy agents have a direct effect on the GI
mucosa causing inﬂammation,
11e13 oedema, ulceration and
atrophy. Increased bowel permeability combined with the
secondary effects of immunosuppression predispose to increased
susceptibility to GI transmural infection potentially leading to
septicaemia, shock, associated hypotension and secondary
mucosal ischaemia.
New-onset lactose intolerance is the cause of diarrhoea and
bloating during 5-ﬂuorouracil chemotherapy in 10% of
patients.
14 15 Clinical experience suggests that small bowel
bacterial overgrowth, bile acid malabsorption and pancreatic
insufﬁciency are three other important contributory factors to
chemotherapy-induced GI symptoms.
16
Hepatic side effects include reactivation of hepatitis B,
17
severe sinusoidal obstruction syndrome (especially oxaliplatin-
based regimens)
18 and steatosis. Following treatment with
irinotecan in particular, steatosis may progress to steatohepa-
titis.
19 This may be exacerbated by pre-existing conditions (eg,
alcohol excess, diabetes and obesity). Both steatosis and stea-
tohepatitis are potentially reversible after cessation of chemo-
therapy but occasionally contribute to morbidity and
mortality.
18e21 The detailed management of these conditions is
described elsewhere.
22
Chronic GI side effects of chemotherapy have not been
studied systematically or prospectively. Clinical experience
suggests that a small proportion of patients do have ongoing GI
problems with constipation, diarrhoea, ﬂatulence, bloating and
pain, and that small bowel bacterial overgrowth is a frequent
cause of these symptoms. However, speciﬁc drugs, their cumu-
lative dose, the degree of immunosuppression during treatment
together with the degree of damage to the mucosa, submucosa
and GI stem cells may also play a role in the development
of chronic problems.
16 23 The interaction with other cancer
treatments complicates the clinical picture further.
Biological agents
Rapidly increasing numbers of biological agents are being
introduced for cancer therapy. This includes both immuno-
therapy and inhibitors of speciﬁc molecular targets. The main
categories of targeted therapies currently include tyrosine kinase
inhibitors (eg, erlotinib, imatinib, geﬁtinib, sorafenib), protea-
some inhibitors (eg, velcade) and anti-angiogenesis agents (eg,
bevacizumab). The spectrum of GI toxicity with these agents
and their causes are poorly deﬁned. Biological agents have
multiple interactions with conventional drugs and, when new
drugs are prescribed, the potential for interactions must
always be checked. It is particularly important for gastroenter-
ologists to know that altering gastric pH in a patient taking
a biological agent orally can markedly affect its bioavailability. In
the emergency setting, if there is any possibility that the bio-
logical agent is the cause of severe symptoms, it is always
acceptable that the agent should be stopped while waiting
for urgent advice from the oncologist treating the patient.
Acute severe GI symptoms should otherwise be managed
normally.
Radiotherapy
Radiotherapy initially causes mucosal changes characterised by
inﬂammation or cell death, but subsequently persistent cytokine
activation in the submucosa leads to progressive ischaemia,
ﬁbrosis and loss of stem cells.
24 These ischaemic and ﬁbrotic
changes potentially cause impairment of GI physiological
function(s). Chemotherapy increases the sensitivity of non-
cancerous tissues to damage from radiotherapy. Chronic GI
dysfunction may follow without pause from acute symptoms
induced by radiotherapy or may arise de novo months, years or
even decades later. The time allowed for follow-up in most
studies prevents the recognition of these late side effects, their
frequency or severity.
25
It is argued that introduction of new chemotherapy and
biological agents and more targeted radiotherapy techniques
over the last two decades will diminish toxicity rates,
26 27 but
the long-term effects of these new cancer treatments are
unknown.
28 For example, the technique of intensity-modulated
radiotherapy (IMRT) has been introduced widely. One possibly
important consequence of IMRT is that more organs are
exposed to low-dose irradiation than was the case with
conventional treatment. It will be some time before deﬁnitive
evidence from clinical trials shows the true impact of this on
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Guidelinesacute and chronic toxicity. Clinical experience suggests that
IMRT simply changes the timing and spectrum of toxicity.
There are virtually no data on the long-term effects of even
newer techniques such as proton beam therapy and cyber knife
treatment.
Surgery
Radical resectional surgery may cause signiﬁcant disruption of
GI physiology. This includes disturbance in intestinal transit,
altered gastric emptying, enzymatic digestion and malabsorp-
tion reﬂecting anatomical disruption and stasis, bacterial over-
growth, altered bile acid secretion and absorption and hepatic
insufﬁciency. Hepatopancreatobiliary resections carry the
inherent risk of subsequent biliary strictures (which may be due
either to benign ﬁbrosis at the anastomosis or disease recurrence)
resulting in obstructive jaundice. In the past, many patients had
limited survival after primary cancer surgery but symptom
complexes which were commondfor example, after upper GI
surgery for peptic ulcerationdare now being observed in long-
term cancer survivors, although many clinicians will no longer
be familiar with these.
Non-resectional ablation techniques
Radiofrequency or microwave ablation and tumour embo-
lisation with a variety of agents including radioactive beads
are being used increasingly with both palliative and curative
intent to treat liver tumours. Complications include ble-
eding, ulceration, ischaemia or perforation of adjacent bowel,
abscess formation, hepatic artery aneurysm and tumour track
seeding.
GI SYMPTOMS: THE ACUTE SYNDROMES
The presentation of GI side effects can be acute, subacute or
chronic (table 1).
Many acute and subacute problems related to cancer treat-
ments will be managed by oncologists. However, increasingly,
potentially life-threatening complications of modern treatments
present via emergency departments.
29
Infection
Neutropenic sepsis is a common complication of cancer
chemotherapy precipitating GI symptoms, which usually
respond quickly to antibiotics. In patients with worsening or
severe diarrhoea, one single stool specimen is sufﬁcient for the
detection of bacteria or toxins, however three separate speci-
mens are required to exclude parasitological causes with
sufﬁcient diagnostic sensitivity. Early endoscopic assessment is
also mandatory as stool culture may not detect viral infection,
toxin-negative Clostridium difﬁcile or drug-induced colitis.
Endoscopy in a neutropenic patient predisposes to sepsis,
although the degree of the increased risk is unclear. Febrile
neutropenic patients should already be on antibiotic therapy.
Recent British Society of Gastroenterology guidelines (grade C
Acute syndromes: key facts
< Urgent cross-sectional imaging may help assessment and
management
< Perform early upper GI endoscopy and duodenal biopsies and
duodenal aspirate and lower GI endoscopy with biopsies for
diarrhoea
< Flexible sigmoidoscopy rather than colonoscopy is usually
adequate initially
< Always consider taking biopsies and asking for histological
evidence of viral infection, especially if multiple ulcers are
seen, even if there has been bleeding
< Ensure platelet support is available before endoscopic
intervention when the platelet count is below 80310
9
< Avoid biopsies from areas of obvious radiation-induced
change unless absolutely necessary
< Colonoscopy is contraindicated in neutropenic enterocolitis
< Infections in the neutropenic patient can kill quickly; early
empirical treatment may be required
< Seek early specialist help
Table 1 Presentation of gastrointestinal side effects: acute, subacute or chronic
Aetiology Acute Subacute Chronic
Infection Bacterial
Viral
Fungal
Opportunistic
Small bowel bacterial
overgrowth
Small bowel bacterial
overgrowth
Inﬂammation
(acute)
Neutropenic enterocolitis
Perforation
Haemorrhage
Graft versus host disease
Pancreatic insufﬁciency
Graft versus host disease Graft versus host disease
Inﬂammation
(chronic)
Bowel obstruction/strictures,
Pancreatic insufﬁciency
Graft versus host disease
Ischaemic/ﬁbrotic Gastric outﬂow obstruction Graft versus host disease,
Pancreatic insufﬁciency
Biliary strictures
Bowel obstruction
Enteropathy and loss
of physiological functions
Graft versus host disease
Pancreatic insufﬁciency
Metabolic Malabsorption
Hepatic insufﬁciency
Malabsorption Malabsorption
Vascular
(ischaemia)
Mesenteric vascular
insufﬁciency
Mesenteric thrombosis
Veno-occlusive disease
Enteropathy and loss of
physiological functions
Vascular
(proliferative)
Telangiectasia causing bleeding
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Guidelinesevidence: expert opinion) suggest that afebrile patients with
a neutrophil count <0.5310
9/l need to be offered antibiotic
prophylaxis only for GI endoscopic procedures associated with
high risk of bacteraemia such as variceal sclerotherapy, oeso-
phageal dilation, laser therapy and endoscopic retrograde chol-
angiopancreatography with biliary obstruction. Gram-negative
aerobic (and, less frequently, anaerobic) bacteria including
Escherichia coli are the most likely pathogens in these conditions,
and the choice of prophylactic antibiotics should reﬂect the local
sensitivities of organisms.
30
The two most important treatable pathogens which regularly
cause severe morbidity or death in patients receiving treatment
for cancer are cytomegalovirus (CMV) and C difﬁcile (10% are
toxin-negative). The type of endoscopic assessment which best
identiﬁes stool culture-negative pathogens is not clearly deﬁned.
However, upper GI endoscopy with duodenal biopsies and
aspirate and ﬂexible sigmoidoscopy with left colonic biopsies
seem to produce results equivalent to full colonoscopy and ileal
biopsy
16 31 32 while avoiding the need for full bowel preparation
and reducing risk.
CMV infection may affect the whole GI tract but is most
commonly found in the oesophagus and colon. Common
symptoms include diarrhoea (up to 80%), bleeding (up to 64%),
fever (up to 50%) and abdominal pain (19e50%). Endoscopy
may demonstrate the presence of multiple ulcers. Serology, viral
culture and PCR techniques are not reliably positive for 3 or
4 weeks after the onset of symptoms. Earlier diagnosis may be
available using the newer shell vial assay and from examination
of endoscopic biopsies. Biopsies should be taken both from the
centre/base of ulcers (site of highest yield for CMV) and from
the edge (which gives a higher yield in herpes simplex virus
infection).
33 34 In a sick immunosuppressed patient with rele-
vant symptoms, early empirical treatment with ganciclovir
should be considered.
The typical endoscopic appearance of Cd i f ﬁcile at ﬂexible
sigmoidoscopy is often diagnostic in toxin-negative patients.
However, pseudomembrane formation requires neutrophil
involvement, and the typical macroscopic and microscopic
appearance may be altered or be completely absent in neutro-
penic patients.
35 Immunosuppressed patients with Cd i f ﬁcile
are at high risk of early progression to fulminant toxic mega-
colon, so delay in investigation and treatment is potentially
dangerous.
Many other pathogens including amoebae, giardia, viruses
such as herpes simplex virus, rotavirus or adenovirus, bacterial
pathogens and fungi may be responsible for symptoms. Recur-
rent infections with different organisms in immunosuppressed
patients may mandate repeated endoscopic reassessments at
short intervals. More than one pathogen may be responsible.
Anorectal sepsis in neutropenic patients is a frequently
forgotten cause of morbidity. Clinical assessment by an experi-
enced colorectal surgeon supplemented by MRI scanning
can often be helpful in detecting an occult site for recurrent
infection.
Typhlitis and neutropenic enterocolitis
Typhlitis and neutropenic enterocolitis carry a high mortality
rate because of the risk of rapid progression to ischaemia,
necrosis, haemorrhage, perforation and multisystem organ
failure. Typhlitis follows chemotherapy-induced neutropenia
and is characterised by inﬂammation localised to the caecal wall,
possibly caused by bacterial invasion. If other parts of the GI
tract are involved (eg, the terminal ileal wall or elsewhere), the
term ‘neutropenic enterocolitis’ is more appropriate. Bowel wall
thickening with or without dilation is usually seen on cross-
sectional imaging. Clinical features include fever, abdominal
pain, nausea, vomiting and diarrhoea. Colonoscopy is contra-
indicated as it carries a very high risk of perforation.
Data on the optimal management are limited. Bowel rest,
intravenous ﬂuids, parenteral nutrition, broad spectrum antibi-
otics and normalisation of neutrophil counts are usually
recommended.
36 When inﬂammation is limited to the caecum
and terminal ileum, clinical experience suggests that most
patients can be managed conservatively. The presence of a local
mass needs repeated imaging to exclude abscess formation or
perforation. Perforation, persistent GI bleeding and clinical
deterioration may mandate surgical intervention. As in the
management of any acute severe colitis, frequent clinical reas-
sessment and early surgical consultation is advised.
Haemorrhage
Causes of bleeding include chemotherapy-induced ischaemia
(particularly induced by taxanes
13 37 and bevacizumab
38),
infections (particularly CMV and Candida), graft versus host
disease (which can occur after stem cell transplantation when
the newly transplanted material attacks the transplant recipi-
ent’s body), autoimmune colitis after treatment with ipili-
mumab,
11 acute radiotherapy-induced ulceration, drug-or
radiotherapy-induced inﬂammatory bowel disease, neutropenic
enterocolitis and oxaliplatin-induced portal hypertension.
39
Patients should be managed like any other high-risk GI bleed.
Experienced endoscopists must be involved from the onset.
Although endoscopy may be more hazardous, early endoscopic
therapy may also be life-saving.
Thrombocytopenia is common in patients with cancer
undergoing chemotherapy. Endoscopists should be aware that,
even with apparently adequate platelet counts, chemotherapy-
induced platelet dysfunction may affect normal homeostatic
mechanisms. There are no robust data as to the minimal safe
platelet count for safe therapeutic endoscopy. Endoscopists
should consider ensuring in advance that platelet support is
available should it be required when performing therapeutic
procedures in patients with a platelet count below 50e80000/ml.
The endoscopic appearance may not be diagnostic without
biopsy. However, even ﬂexible endoscopic biopsy under
direct vision can be hazardous in the presence of thrombocyto-
penia, incipient ischaemic necrosis or previous radiotherapy,
especially brachytherapy. Endoscopic intervention may be
sufﬁcient for bleeding from discrete sites, but interventional
radiology with embolisation or surgery may be required in
extensive mucosal change. Hyperbaric oxygen therapy is prob-
ably the treatment of choice for radiotherapy-induced bleeding
occurring at multiple sites throughout the small and/or large
bowel.
40e42
Perforation
Perforation may result from spontaneous tumour necrosis,
which may or may not be due to chemotherapy or progression
of cytotoxic drug-induced ulceration, often on a background of
adjunctive corticosteroid or non-steroidal anti-inﬂammatory
drug treatment. The antivascular endothelial growth factor
monoclonal antibody bevacizumab causes ulceration, ﬁstula-
tion or free perforation in 0.9% of patients within 1 year of
treatment.
43 This may be at the primary tumour site but also
within colonic diverticula or otherwise normal areas of stomach
and duodenum. Bevacizumab may increase the risk of stent-
related
44 and spontaneous perforation and is associated with
bleeding, poor wound healing and thromboembolism. Two
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Guidelinestyrosine kinase inhibitors, erlotinib and geﬁtinib, are also
associated with bowel perforation. Surgical treatment is
essential as long as the patient is ﬁte n o u g h ,a n dt h e r a p e u t i c
resection may be the best approach if the primary tumour has
perforated. If circumstances permit, referral to a specialist
surgeon is indicated.
Mesenteric ischaemia and infarction
Spontaneous mesenteric vascular insufﬁciency can be induced by
the hypercoagulable state associated with some cytotoxic
agents.
45 This can affect both diseased and unaffected small
bowel. The mortality rate is high and a high degree of suspicion
is needed to diagnose ischaemia. The aetiology may be venous or
arterial and expert radiology may help in assessment and
management. Optimal management of acute intestinal
ischaemia requires early assessment by an experienced surgical
team. The optionsddepending on the general state of the
patientdinclude full anticoagulation if the bowel is viable,
through to staged resection, often requiring repeat laparotomies
and open abdomen techniques.
Chemotherapy-associated mesenteric ischaemia can present
with acute abdominal pain, but also can produce small bowel
strictures causing small bowel obstruction. It must be treated by
a combination of nutritional support, repeated clinical assess-
ment by experienced surgeons and appropriate anticoagulation.
Hepatic veno-occlusive disease/portal vein thrombosis
This is a very frequent cause of early mortality among patients
receiving high-dose chemoradiation or stem cell trans-
plantation.
46 Activation of the coagulation cascade and inﬂam-
matory processes following endothelial injury results in
a hypercoagulable state. The possibility must always be consid-
ered in patients presenting with jaundice, pain or ascites. Many
patients will, however, have rather non-speciﬁc symptoms or
biochemical changes and early CTscanning with contrast may be
diagnostic. Early anticoagulation may be life-saving.
Bowel obstruction
Obstruction usually affects the small bowel or, after pelvic
radiotherapy, the sigmoid. Several factors may contribute in
individual patients. It may develop as a result of benign causes
such as changes in intestinal transit, medical causes (see below),
adhesions or radiotherapy-induced ﬁbrosis, or malignant causes
such as recurrent cancer or peritoneal carcinomatosis.
Acute small bowel obstruction
This should be managed conservatively initially with anal-
gesia, intravenous ﬂuids, nutritional support and nasogastric
aspiration unless there is suspicion of strangulation requiring
emergency surgery. Cross-sectional imaging, which sometimes
is difﬁcult to interpret accurately, may be helpful to estimate
the level of obstruction and whether it is complete or incom-
plete. The possibility of multiple sites of partial obstruction
needs to be carefully considered as this may limit surgical
options.
Subacute bowel obstruction
Experience suggests that important medical causes include
abnormal electrolyte balance, opioid drugs, small bowel bacterial
overgrowth, excessive faecal loading, severe fat malabsorption
and excessive dietary ﬁbre.
A trial of antibiotics and/or a low-fat diet (if steatorrhoea is
present) and/or treatment with a bile acid sequestrant as
appropriate may help. If the radiology suggests focal colonic
faecal loading or a colonic site of obstruction or there is iron
deﬁciency anaemia, colonoscopy should be considered. Excess
ﬁbre in the diet may precipitate subacute obstruction if a stric-
ture is present. Some patients are very sensitive to opiates
and can have prolonged colonic inertia even following small
doses.
If low-ﬁbre diets are indicated they should be prescribed by
a qualiﬁed dietitian, should initially be time limited and the
clinical beneﬁt from the diet reviewed. Additional laxatives may
be required. Data may emerge for the role of hyperbaric oxygen
in treating patients with subacute obstruction due to radiation-
induced ﬁbrosis from the national ongoing HOT 2 trial
(EudraCT No 2008-002152-26).
Surgery with a view to releasing adhesions or resecting stric-
tures after previous pelvic radiotherapy can be particularly
challenging because of dense abdominal ﬁbrosis, and carries
signiﬁcantly higher risks of complications (eg, anastomotic
leakages, postoperative intra-abdominal sepsis and intestinal
ﬁstulation) than surgery in a non-irradiated patient. Such
surgery should be performed only by experienced surgeons with
a low threshold for proximal faecal diversion. If an enteric
motility disorder is also present (not uncommon), surgery may
not lead to resolution of the symptoms.
Obstruction due to recurrent cancer
If cancer is present, the nature of the intervention should be
inﬂuenced by the expected prognosis of the recurrence. Selected
patients with no ascites, life expectancy >2 months and good
performance status may beneﬁt from palliative decompressive
surgery, but placement of self-expanding metal stents (if
possible) appears to offer a better outcome.
47 Expert medical
management with opioids, antispasmodics (eg, hyoscine butyl
bromide), antiemetics, antisecretory agents (eg, octreotide),
corticosteroids and nasogastric tubes or venting gastrostomies
can be effective in helping to control symptoms. Early
input from surgeons and palliative care specialists should be
sought.
48
GI SYMPTOMS: THE CHRONIC SYNDROMES
The GI tract can only respond to pathological processes in
a limited number of ways, so different pathological processes
may produce identical symptoms. Many patients treated for
cancer have other pre-existing illnesses and lifestyles which
predispose to cancer and also to chronic GI symptoms after
cancer treatments.
16 49 New incidental GI conditions may
develop or manifest themselves coincidentally around the time
the cancer is treated or thereafter. Patients may be taking
medications or have made dietary changes affecting GI
function.
There are ample data to suggest that symptom clusters often
labelled as ‘typical syndromes’dfor example, ‘bleeding from
Chronic syndromes: key facts
< Symptoms are unreliable at identifying the underlying cause
< Many cancer treatments have systemic effects and are not
limited by normal anatomical boundaries
< Patients may not report even severe symptoms reliably
< Patients and clinicians may differ as to what constitute
signiﬁcant symptoms.
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Guidelinesproctitis’ or ‘subacute obstruction due to adhesions’dare unre-
liable at predicting the true underlying cause of symptoms.
50e55
Part of the reason for this is that many cancer treatments are
systemic and do not respect conventional anatomical bound-
aries. One-third of symptoms conﬁdently attributed to cancer
therapy are found after investigation to be unrelated to the
cancer treatment.
51 A more valuable approach is to pay
attention to the full clinical picture and consider all options.
50 51
Incidence and prevalence ﬁgures
GI side effects are underestimated in the literature and within
clinical trials.
56e58 Case notes frequently do not record side
effects except when patients require surgery as part of their
management.
59 60 When prospective data are available,
3 they
are invariably based on symptom questionnaires rather than
objective markers. Many current questionnaires are inade-
quately sensitive, do not use reproducible methodology and
ignore issues important for patientsdfor example, severe ﬂat-
ulence or urgency of defaecation.
49 61e65 Focusing on symp-
toms without conﬁrmatory objective investigations is also
potentially misleading. Common bowel disorders produce
identical symptoms to those arising as side effects of cancer
therapies.
34 96 6There is an urgent need for better tools which
can be applied in routine clinical practice to measure side
effects accurately.
67
Clinician, patient and treatment factors
Some patients will not report symptoms because they are too
embarrassed or feel nothing can be done.
10 Clinicians may not
understand the signiﬁcance of patients’ symptoms or their
relationship to previous cancer treatments or simply ignore
them.
61 Health professionals seeing these patients need to
develop strategies to identify proactively unexpected symptoms
potentially amenable to treatment.
Different problems and rates of late effects occur depending
on speciﬁc treatments and how they are combined. Table 2
shows the rate and nature of problems for a wide variety of
cancers and table 3 shows how different treatments for the same
cancer can have different toxicity proﬁles.
The non-speciﬁc nature of these post-treatment symptoms,
which often occur in combination, requires a systematic
approach to unravel the associated, sometimes complex, clinical
causes. In patients attending a specialist clinic for late GI effects
after cancer therapy, more than half were found to have more
than one cause for their symptoms.
50 For each speciﬁc symptom
there are a number of potential diagnoses. Using a systematic
Table 2 Rate and nature of chronic gastrointestinal problems after cancer treatment in patients at different tumour sites
Cancer
site
Numbers of
diagnoses
annually in UK
Numbers
undergoing
treatment with
curative intent
Treatment
modalities
Survival at 5 years
after radical treatment
Percentage
affected by chronic
symptoms affecting
quality of life
Types of chronic
GI symptoms
Oesophago-gastric 13000 20% Chemotherapy
Radiotherapy
Surgery
25e30% 50% (?) Anorexia
Diarrhoea
Nausea
Reﬂux
Weight loss
Pancreas 6500 10e15% Chemotherapy
Radiotherapy
Surgery
14%e25% N/A Malabsorption
Weight loss
Wind
Colorectal 38600 90% Chemotherapy
Radiotherapy
Surgery
50% Colonic surgery: 15%
Rectal surgery: 33%
Short-course radiotherapy:
66%
Chemoradiation +
surgery: 50%
Bleeding
Diarrhoea
Frequency
Incontinence
Tenesmus
Urgency
Anal 1000 80% Chemoradiation
(Surgery)
40%e70% N/A Bleeding
Frequency
Incontinence
Urgency
Gynaecological 18000 90% Surgery
Radiotherapy
6 Chemotherapy
Variable
Depending
on tumour type
40% after treatment which
includes radiotherapy
Bleeding
Diarrhoea
Flatulence
Frequency
Incontinence
Malabsorption
Pain
Urgency
Head and neck 9000 90% Chemoradiation
20e25%
Surgery
>50% Up to 50% Dysgeusia
Dysphagia
Dependency on
tube feeding
Pain
Trismus
Weight loss
Xerostomia
Urological 50000 80% Chemotherapy
Radiotherapy
Surgery
75% 30% after radiotherapy Bleeding
Constipation
Diarrhoea
Flatulence
Frequency
Incontinence
Malabsorption
Pain
Urgency
Data compiled from a number of references
36 8 e79 see also http://info.cancerresearchuk.org/cancerstats/types/
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Guidelinesalgorithmic approach, there are standard tests which may
elucidate the diagnosis or diagnoses causing each speciﬁc
symptom.
35 05 19 49 5For each diagnosis made, a number of
possible established and experimental therapies are available.
Anecdotal evidence suggests that such a systematic approach
can improve symptoms by an average of 70e90%. The efﬁcacy
of such an algorithmic approach in patients with GI symptoms
after pelvic radiotherapy is currently being tested in a large,
almost completed, randomised clinical trial (ORBIT study,
ISRCTN 22890916).
HISTORY, EXAMINATION, INVESTIGATIONS AND TREATMENT
To date, there has been no coordinated approach to improve the
lot of this group of patients. Health professionals who regularly
see these patientsdmedical and clinical oncologists, GI,
urological and gynaecological surgeons, specialist nurses and
general practitionersdmay not have the expertise to manage
these patients’ symptoms optimally. However, when they
identify patients who need and want helpdand table 4
suggests that almost all the patients who would beneﬁtf r o m
help can be identiﬁed with just three simple questionsdthey
must have an established referral pathway for those patients.
Most patients should be referred to gastroenterologists but
appropriate referral pathways, either to regional centres or
locally, are best developed after discussion within the local
cancer multidisciplinary team.
Managing symptoms
A systematic approach to managing symptoms will only func-
tion usefully if a clinician can clearly elicit an accurate history
from the symptomatic patient who has often undergone
complex multimodal treatments. Many patients do not under-
stand precisely the details of previous cancer treatments, which
sometimes have gone on for years and may still be continuing,
and are frequently frightened that any persistent symptom is
a manifestation of recurrent cancer. Contacting the oncologists
and surgeons at the cancer centre for precise details of previous
treatments frequently changes management.
History
In addition to a detailed history relevant to the GI tract, it is
important to remember that, especially after previous pelvic
radiotherapy, patients will also often have other urinary, sexual,
psychological and occasionally neurological symptoms which
inﬂuence or are inﬂuenced by their GI problems. Bone disease
(eg, pelvic insufﬁciency fractures) and lymphoedema are
also common and may also have not been previously detected
or dealt with and may be the cause for some or all of their
problems.
90 92 98 99
Dietary habitsdexcess ﬁbre (from ‘healthy eating’), inade-
quate ﬁbre, alcohol excess or unhelpful nutritional supplements
(eg, excess selenium causing nausea, diarrhoea and halitosis)d
may contribute to or be the sole cause of chronic GI symptoms
surprisingly commonly. Consultations which include input from
the patient’s partner often improve the quality of the history
obtained.
Examination, investigations and treatment
An appropriate physical examination is required. Basic initial
investigations should include haematological and biochemical
proﬁles, inﬂammatory and tumour markers. In addition, clinical
experience and limited published data suggest that a number of
other tests are particularly worthwhile in patients who are
symptomatic after cancer treatments (box 1).
50
Speciﬁc investigations should be tailored for the principal
symptoms and should reﬂect an understanding of the potential
aetiologies. For example, there are at least 13 different causes for
diarrhoea after pelvic radiotherapy, most of which require
different treatments, and ﬁve different causes for new-onset
steatorrhoea (table 5).
Faecal incontinence affects up to 50% of patients after rectal
cancer and one in ﬁve patients after pelvic radiotherapy. Few
Table 3 Frequency of chronic toxicity from different treatments for
rectal cancer
Symptoms
Surgery
alone
Preoperative
radiotherapy
Postoperative
radiotherapy
Any incontinence 5e38% 51e72% 49e60%
Toilet dependency 6% 30% 53%
Loose stool 2e5% N/A 25e29%
Bowel obstruction 4e11% 5e13% 11e15%
Excellent bowel
function
32% 14% N/A
Data compiled from a number of references.
80e93
General management strategies: key facts
< Gastrointestinal symptoms identiﬁed as starting after cancer
treatment are frequently not related to the cancer treatment
< Many patients have more than one cause for symptoms
< Many cancer treatments are systemic and may cause side
effects throughout the gastrointestinal tract
< Symptoms are unreliable at predicting the underlying cause
< Inappropriate treatment has a signiﬁcant potential for causing
harm (box 5)
< Most patients need appropriate investigation before treatment
< Contacting the oncologists and surgeons for details of
previous treatments frequently changes management.
Table 4 Questions to identify patients in need of specialist assessment
Critical minimal questions
indicating need for GI referral
Critical minimal indicators to
consider endoscopic assessment
Are they woken from sleep to
defaecate?
Is the patient $5 years after radiotherapy
(screening for second malignancy)?
Do they have troublesome urgency
of defaecation and/or faecal
leakage/soiling/incontinence?
Is there any rectal bleeding?
Do they have any GI symptoms
preventing them from living a full life?
Data compiled from references
96 97
Box 1 Useful initial investigations
< Vitamin B12 levels
< Thyroid function tests
< Coeliac screen
< Selenium homocholic acid taurine (SeHCAT) scan
< Glucose hydrogen/methane breath test
< Upper GI endoscopy + duodenal aspirate
< Flexible sigmoidoscopy
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Guidelinespatients are referred for specialist evaluation, let alone support
by incontinence services. Most commonly, evaluation is offered
by coloproctologists. However, in those who have had pelvic
radiotherapy or chemotherapy, faecal incontinence is often at
least partly due to small bowel causes leading to intestinal hurry
(especially small bowel bacterial overgrowth and bile acid
malabsorption). Appropriate investigations are required when
loose stool or erratic bowel function is present, and standard
therapeutic approaches to faecal incontinence aimed mainly at
local anorectal causes have proved to be ineffective.
61
Rectal bleeding from radiation-induced telangiectasia after
pelvic radiotherapy
The dose of radiotherapy delivered to the anterior rectal wall
determines the risk of bleeding from telangiectasia.
100 Bleeding
occurs in 50% of patients after pelvic radiotherapy but impairs
quality of life requiring intervention in fewer than 6%. Telan-
giectases often heal spontaneously over 5e10 years. Patients
with any rectal bleeding should be offered at least ﬂexible
sigmoidoscopy because of the high prevalence of unexpected
pathology. All currently available interventions (endoscopic,
surgical and hyperbaric oxygen therapy) for radiotherapy-
induced bleeding are not risk-free. The only four treatments
with any evidence of beneﬁt in randomised trials (of very vari-
able quality) are sucralfate enemas,
101 4 weeks of treatment
with metronidazole,
102 vitamin A
103 and hyperbaric oxygen
therapy (ﬁgure 1A,B).
42
Table 5 Common physical causes for diarrhoea or steatorrhoea after
cancer treatment
Diarrhoea Steatorrhoea
Bile acid malabsorption Bile acid malabsorption
Carbohydrate malabsorption Free fatty acid malabsorption
Constipation with overﬂow Intestinal lymphangiectasia
Dietary/alcohol problems Pancreatic insufﬁciency
Drug side effects Small bowel bacterial overgrowth
Endocrine abnormalities
Infection
New/recurrent neoplasia
New-onset primary inﬂammatory
bowel disease
Rapid transit
Short bowel syndrome
Small bowel bacterial overgrowth
Stricture formation
Figure 1 (A) Painful rectal ulceration
following argon beam ablation for
radiation-induced bleeding after
treatment for prostate cancer. (B)
Almost complete resolution of
ulceration after 40 sessions of
hyperbaric oxygen therapy.
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GuidelinesMany gastroenterologists consider that argon plasma coagu-
lation (APC) is the treatment of choice. However, it should be
used with considerable caution in this patient group. It is not
widely appreciated that the published literature can be inter-
preted as showing that the serious complication rate for APC
when used for radiation proctopathy is potentially as high as
26%.
9 51 Some of these disastrous complicationsdsuch as
explosions following use of APC in inadequately prepared
boweldare preventable. Others, such as the occurrence of deep
ulceration,
104e106 ﬁstulation,
107 stricture formation,
104 108 109
bleeding,
105 106 110 perforation
105 and severe sometimes chronic
pain,
110e112 reﬂect the risk of any thermal therapy in chronically
ischaemic tissues. It may be that restricting argon ﬂow rates and
wattage and very precise and brief application of the argon
catheter would reduce complication rates,
113 but this has not
been proved. Anecdotal evidence suggests that, where bleeding is
heavy, APC frequently fails. In specialist centres, serious
complications of previous APC treatment in this patient group
continue to be seen regularly.
The other treatment commonly prescribed is regular applica-
tion of corticosteroid enemas. The evidence from randomised
trials suggests minimal or no beneﬁt from their use.
114 This is
unsurprising as the chronic pathophysiology of radiation-
induced damage is largely ischaemic and not inﬂammatory.
24 If
topical treatment is used, sucralfate enemas (box 2) are clearly
more effective than corticosteroid enemas.
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All the options for treatment of radiation-induced telangiec-
tasia are listed in table 6. Evidence for long-term outcomes from
any of the treatments is very scanty.
In the absence of any comparative studies of the various major
treatment modalities of radiation-induced rectal bleeding, one
clinical approach for patients with radiation-induced rectal
bleeding which reduces risk to a minimum is as follows:
Step 1: Investigate with ﬂexible endoscopy to determine the
cause of the bleeding.
Step 2: Optimise bowel function and stool consistency which
may reduce the amount of bleeding.
Step 3: If bleeding is not affecting quality of life (eg, staining
clothes, causing anaemia, interfering with daily activities),
reassure and do nothing further.
Step 4: If bleeding affects quality of life, stop/reduce anti-
coagulants if possible and, if very severe, start sucralfate enemas
(box 2),
Step 5: Discuss deﬁnitive treatment to ablate the telangiectasia
with the patient; current options include:
a. hyperbaric oxygen therapy (advantages: supported by RCT
evidence, may reverse progressive changes caused by radio-
therapy, may improve other symptoms such as urinary
problems; disadvantages: time-consuming (8 weeks of daily
treatment), expensive and patients may need to travel long
distances to their nearest unit);
b. argon plasma coagulation (advantages: easily available and
simple; disadvantages: signiﬁcant risk and unproven efﬁcacy
in heavy bleeding);
c. formalin therapy (advantages: simple to perform; disadvan-
tages: long-term outcomes poorly known, small risks of
serum sickness, severe proctitis or chemical burn to the skin if
there is spillage).
Dysphagia/retching/nausea after cancer therapies including
upper GI surgery
This is a common cause for referral. A suggested approach is
given in table 7. Clinical experience suggests that gastric bile
reﬂux and small bowel bacterial overgrowth are commonly
forgotten causes of nausea in patients during and after cancer
therapy. Strictures are often found on endoscopy and an
approach to stricture management in the upper GI tract is
shown in table 8. If nausea and vomiting persist after metabolic
causes have been excluded, endoscopy with or without radiology
have revealed no cause and trials of routine therapy have not
helped, a brain scan should be considered.
Dumping syndrome
When gastric emptying is rapid it leads to ‘dumping syndrome’,
characterised by GI and vasomotor symptoms that occur after
meals. This can be soon after meals or delayed for up to several
hours. The physiological causes are complex, but include the
high osmolarity of small bowel contents and reactive hypo-
glycaemia. The diagnosis of early dumping is usually made on
clinical grounds, although rarely gastric scintigraphy is helpful.
Late dumping can be diagnosed by measuring blood glucose
when patients are symptomatic. If the presentation is atypical,
the rare possibility of an insulinoma should be considered. Initial
management should be dietary advice to reduce the volume and
Box 2 Making up and using sucralfate enemas
Sucralfate enemas
< 2 g sucralfate suspension
< Add to 30e50 ml tap water
< Draw up in a bladder syringe
< Fit a soft Foley catheter to the syringe
< Lubricate the catheter and pass into the rectum
< Inject the sucralfate mixed with water twice a day into the
rectum
< Retain the enema for as long as possible
< Initially roll through 360
o to coat the entire rectal surface
< Lying prone then best covers anterior wall rectal telangiec-
tasia, the likely area of greatest bleeding
Table 6 Therapeutic options for radiation-induced rectal bleeding
Treatment modality Comments
Medical therapies
Sucralfate enemas 1 RCT,
101 several case series
Metronidazole 1 RCT
102 used for 4 weeks in combination
with corticosteroids and mesalazine (these
last two agents probably ineffective if used
alone). Possibly contraindicated if patient has
already developed chemotherapy-induced
peripheral neuropathy
Vitamin A (retinol palmitate) 1 small RCT
103 and no endoscopic assessment
performed
Sulfasalazine Case series
Thalidomide Case report
Short chain fatty acids Inconclusive RCT
115
Rebampide enema therapy Case series (not available in the UK)
Other therapies
Hyperbaric oxygen treatment I RCT,
42 several case series
Endoscopic laser ablation Multiple case series, different lasers used.
Endoscopic argon plasma
coagulation
Multiple case series, serious complication rate
7-26%
Endoscopic formalin application Multiple case series, outcomes poorly assessed
Surgical application of formalin Multiple case series, outcomes poorly assessed
Other references.
6 7 116
RCT, randomised controlled trial.
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Guidelinesosmolarity of food presented to the small intestine and the
avoidance of ﬂuids taken with meals. Loperamide, guar gum or
pectin to slow gastric emptying may be helpful. For late
dumping, acarbose may sometimes help. Octreotide or lanreo-
tide are helpful in the short term. Studies have shown mixed
results when these drugs were evaluated longer term. Surgical
revision of the roux-en-Yanastomosis is a complex procedure but
can be effective in selected cases.
ROLE OF HEALTH PROFESSIONALS IN THE LATE EFFECTS TEAM
Cancer clinical nurse specialists (CNS) are ideally placed to
undertake the end of treatment assessment with the patient.
The CNS is usually in contact with the patient throughout their
cancer journey. They undertake a key role in the liaison with all
members of the multidisciplinary team as well as care providers
in the community or referring units. They will be available to
offer support and information to patients and their carers and
increasingly take on a ‘key worker’ role ensuring the smooth
running of the patient pathway.
The CNS is an autonomous practitioner who may run their
own nurse-led clinics during treatment or in follow-up and
many continue to develop their role, taking on advanced
assessment and prescribing as part of their practice. They should
encourage patients to seek help for any new symptoms. It is
essential that they are able to recognise those with ongoing
effects of their therapy so they can identify them to the
oncologist and to support referral for gastroenterological
opinion.
Patients who are well informed about their disease and its
treatment, the possible effects they may experience and services
available to help and support them have a greater chance of
achieving a better quality of life within the constraints of their
condition. Many sources of information are available to patients,
but they may need direction to information that is of a high
quality and is relevant to them; they may need help to interpret
the information. They should be offered information in
a language and format that is acceptable to them so that they
can make decisions regarding their care and condition where
possible. It may also be helpful to direct patients to local support
groups where they exist.
Specialist dietetic help is often required (boxes 4 and 6).
Weight loss and weight gain (the metabolic syndrome) can be
problems after cancer treatment. However, new groups at risk
are frequently being deﬁned. As many as 40% of patients with
metastatic colorectal cancer at presentation have lost signiﬁcant
amounts of weight and have not regained it at 1 year.
118 About
10% of patients develop very severe toxicity (mostly bowel
toxicity) after chemoradiation for cervical cancer, which can lead
to signiﬁcant nutritional issues.
119
Often these patients have complex causes for their symptoms
which need multiple investigations by the gastroenterologist,
51
and then joint management by the gastroenterologist and die-
titian (box 3) which may include dietary ﬁbre manipulation,
reduced fat diets and changes in carbohydrate intake, especially
lactose and fructose. In these patients, dietary adequacy and
mineral and vitamin status are often compromised and need
formal assessment and, if necessary, treatment with dietary
advice or speciﬁc micronutrient supplements.
Table 7 Investigation and management of dysphagia/retching
Investigations of choice Differential diagnosis Therapeutic options
CT+PET
scan6endoscopy
Tumour progression/recurrence Refer back to MDT
Endoscopy Benign stricture Dilation6self-expanding plastic/removable metal
stent, long-term acid/bile suppression, dietetic
advice/enteral feeding tube
Inﬂammatory (acid/bile/
pepsin-related)
Sucralfate/proton pump inhibitor/
promotility agents
Infection (fungal/viral small bowel
bacterial overgrowth)
Speciﬁc antibiotic
Radiological contrast
swallow6endoscopy
Spasm/abnormal peristalsis Calcium channel antagonists, low-dose
antidepressants
Dysmotility/reﬂux/slow transit
through upper GI tract
Sucralfate/proton pump inhibitor/promotility
agents (domperidone, low-dose erythromycin
(250 mg bd), paroxetine, subcutaneous
naloxone), dietetic advice, enteral feeding tube
MDT, multidisciplinary team; PET, positron emission tomography.
Table 8 Endoscopic management of oesophageal strictures
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Nature of stricture Advice
Anastomotic/tumour/
radiation
Should be performed only by experienced endoscopists
If tumour is present, endoscopic intervention
should only occur after MDT discussion
Dilate to a maximum diameter of 15e20 mm
Dilate for 20e60 s if using a balloon
Dilation >12 mm not required for stent insertion
Do not exceed diameter of the stricture by
>7e8 mm per session
Risks are increased after chemotherapy/radiotherapy/if
tumour is presentTemporary/permanent stent placement
may be required after dilation
Box 3 An approach to other common problems after pelvic
radiotherapy
Mucus discharge/leakage
< Ensure that ﬁbre intake is not excessive
< Provide pelvic ﬂoor and toileting exercises
< Stool bulking agent and/or antidiarrhoeal agent
Excess rectal ﬂatulence
Consider:
1. Dietary: excess/deﬁciency of ﬁbre intake and inadequate ﬂuid
intake
2. Colonic faecal loading
3. Small intestinal bacterial overgrowth
4. Organic cause (eg, neoplasia, inﬂammatory bowel disease)
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GuidelinesCONCLUSIONS
Substantial progress has been made in treating cancer. However,
there are convincing and consistent data that large numbers of
people have chronic physical morbidity after cancer treatment
which commonly affects the GI tract and impacts adversely on
daily activities. There is a professional obligation to identify
systematically patients with such unmet needs and to develop
appropriate referral pathways where they do not currently exist.
This multidisciplinary guidance is designed to help those
clinicians who wish to understand better the underlying
pathology and current management options for physical
symptoms. It is hoped that it may form the starting point for
multidisciplinary team discussions to enhance care for these
patients and for educational programmes for trainees who need
to know how to manage these issues. Systematic education
about the optimal management of severely symptomatic
Box 4 Research priorities
Important research themes
< How are patients with chronic GI effects of cancer therapies best detected?
< What are the best objective tools to measure the severity of chronic gastrointestinal problems?
< What are the best objective biomarkers of damage to non-cancerous tissues?
< What are the frequency and nature of chronic GI symptoms after different cancer treatments which affect patients’ day to day activities?
< How can quality of life scores be used to quantitate ongoing symptoms?
< Who should manage chronic symptoms?
< By what stage should patients be referred for specialist evaluation?
< What treatments work for late side effects?
< How are chronic side effects best prevented?
Important achievable clinical trials which are urgently required
< Randomised trials of optimal therapy for faecal incontinence/anterior resection syndrome after surgery
< Randomised trials of conservative treatment versus hyperbaric oxygen/argon plasma coagulation/intrarectal formalin for radiation-
induced bleeding
< Randomised trials of nurse-led management versus doctor-delivered care for GI late effects
< Randomised trials of promotility agents for gastroparesis after upper GI surgery
< Randomised trials of antiﬁbrotic agents soon after completion of radiotherapy to ameliorate chronic progressive ﬁbrosis and hence
symptoms
< Randomised trials of PEG feeding versus nasogastric tube feeding to prevent chronic feeding problems in patients undergoing treatment
for head and neck malignancy
High quality clinical series which will quickly impact clinical outcomes
< What are the physiological abnormalities which accompany chemotherapy-induced diarrhoea (eg, lactose intolerance, bile acid
malabsorption, small bowel bacterial overgrowth)?
< Small bowel bacterial overgrowth after cancer treatment, what organisms and when?
Important unanswered questions
< Outcomes of low-ﬁbre diets for intermittent small bowel obstruction
< Role of low-fat diets in patients with steatorrhoea
Box 5 Clinicians beware!
Clinicians beware!
< Fixed, impassable and easily perforated sigmoid on endoscopy in patients with gynaecological cancer after combination chemotherapy +
radiation 6 surgery.
< Endoscopic biopsy of the anterior rectal wall in patients who have had brachytherapy is associated with a 2% rate of ﬁstula formation
< Mesalazine exacerbates acute radiation-induced intestinal inﬂammation
< There is minimal chronic inﬂammation after radiotherapy so corticosteroids have no role in the management of chronic symptoms
< Patients with steatorrhoea are usually misdiagnosed as having diarrhoea
< Hepatic veno-occlusive disease is an emergency
< Small bowel bacterial overgrowth can cause any GI symptom including subacute obstruction
< Tissues which have been exposed to radiation may not heal normally after biopsy or polypectomy
< Endoscopic or surgical intervention in irradiated tissues is an intervention within a potentially ischaemic ﬁeld
< There is a reported rate of serious complications of 7e26% for argon beam ablation of rectal radiation-induced telangiectasia
< Only two treatments have been shown with any degree of conviction in controlled trials to be effective for radiation-induced rectal
bleeding from telangiectasia: sucralfate enemas and hyperbaric oxygen therapy
< Don’t forget common medical causes of recurrent subacute obstruction
< Low levels of faecal elastase only diagnoses pancreatic insufﬁciency reliably after small bowel bacterial overgrowth has been excluded
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Guidelinespatients is sorely lacking, despite the fact that the number of
affected patients in the UK currently equals the number of
patients diagnosed annually with primary inﬂammatory bowel
disease, and is increasing by 3% per year. This patient group can
undoubtedly gain substantial beneﬁt from a more coherent
approach to care for their ongoing and often disabling and
distressing symptoms.
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